Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2014
03/13/2014WO2014039502A1 Bolaamphiphilic compounds, compositions and uses thereof
03/13/2014WO2014039500A1 Bolaamphiphilic compounds, compositions and uses thereof
03/13/2014WO2014039489A1 Spirocyclic derivatives as antiparasitic agents
03/13/2014WO2014039484A1 Spirocyclic isoxazolines as antiparasitic agents
03/13/2014WO2014039452A1 Methods of treating a bruton's tyrosine kinase disease or disorder
03/13/2014WO2014039434A1 Alkoxy pyrazoles as soluble guanylate cyclase activators
03/13/2014WO2014039421A1 Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
03/13/2014WO2014039412A1 Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
03/13/2014WO2014039411A1 Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
03/13/2014WO2014039375A1 Method of adjuvant cancer treatment
03/13/2014WO2014039223A1 Diagnosis and treatment of aspirin-exacerbated respiratory disease (aerd)
03/13/2014WO2014039138A1 Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease
03/13/2014WO2014039042A1 Novel cannabinergic compounds and uses thereof
03/13/2014WO2014039012A1 Hyaluronic acid-based drug delivery systems
03/13/2014WO2014039011A1 Methods to inhibit intracellular growth of bacteria and to treat bacteria-mediated diseases
03/13/2014WO2014039001A1 Tiotropium preparations
03/13/2014WO2014038895A1 Solid oral dosage form containing valsartan, and preparation method therefor
03/13/2014WO2014038894A1 Ethyl(2-methyl-3{(e)-[(naphtha[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1h-indole-1-yl)acetate, and composition comprising analogues thereof as active component, for preventing and treating cancer
03/13/2014WO2014038882A1 Novel compound, and use thereof for inhibiting interleukin-1 beta or interleukin-6
03/13/2014WO2014038881A2 Protein kinase inhibitor comprising pyridine derivatives
03/13/2014WO2014038873A1 COMPOSITION FOR INHIBITING CELLULAR SENESCENCE COMPRISING QUERCETIN-3-O-β-D-GLUCURONIDE
03/13/2014WO2014038872A1 Composition for inhibiting cellular senescence comprising loliolide
03/13/2014WO2014038653A1 Production method for kidney-derived somatic stem cells
03/13/2014WO2014038630A1 Cesium-excreting agent, poisonous metal-excreting agent, food or beverage, feed, and medicinal product
03/13/2014WO2014038623A1 3-(4-piperidyl)-indazole derivative
03/13/2014WO2014038606A1 Crystal of dispiropyrrolidine derivative
03/13/2014WO2014037900A1 Indole carboxamide derivatives and uses thereof
03/13/2014WO2014037751A1 Pharmacologically active compounds
03/13/2014WO2014037750A1 Inhibitor compounds
03/13/2014WO2014037727A1 Carcainium salts
03/13/2014WO2014037726A1 Liquid pharmaceutical compositions
03/13/2014WO2014037686A1 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
03/13/2014WO2014037563A1 Process for preparing cinacalcet and pharmaceutically acceptable salts thereof
03/13/2014WO2014037546A1 Oleoylethanolamide compositions
03/13/2014WO2014037532A1 Methods of treating alzheimer's disease and pharmaceutical compositions thereof
03/13/2014WO2014037528A1 Composition comprising licoricidine
03/13/2014WO2014037480A1 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
03/13/2014WO2014037417A1 Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
03/13/2014WO2014037416A2 New therapeutic approaches for treating parkinson's disease
03/13/2014WO2014037412A1 Nootropic compositions for improving memory performance
03/13/2014WO2014037381A1 Method for treating pruritus
03/13/2014WO2014037377A1 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
03/13/2014WO2014037362A1 Inhibitors of bromodomain-containing protein pcaf for the treatment of autoimmune and inflammatory diseases or for the treatment of cancer
03/13/2014WO2014037343A1 Composition for treating psoriasis
03/13/2014WO2014037327A1 N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof
03/13/2014WO2014037303A1 Lpar - substituted cyanopyrazole compounds
03/13/2014WO2014037121A1 Use of rifapentine in the treatment of tuberculosis in patients infected with the human immunodeficiency virus (hiv) / acquired immune deficiency syndrome (aids) and treated with an antiretroviral combination
03/13/2014WO2014037022A1 Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
03/13/2014WO2014036956A1 Crystal forms of azetidinone compounds and preparing methods thereof
03/13/2014WO2014036954A1 Transmucosal administration of taxanes
03/13/2014WO2014036953A1 Polymorphs of aromatic urea for use in antineoplastic medicament and methods for preparing the polymorphs
03/13/2014WO2014036897A1 Imidazoline derivatives, preparation methods thereof, and their applications in medicine
03/13/2014WO2014036865A1 Method for preparing fingolimod mucate and crystal thereof and application of fingolimod mucate and crystal thereof
03/13/2014WO2014036655A1 Treatment of diarrhea and post-weaning diarrhea with resistant potato starch
03/13/2014WO2014036654A1 Compounds and methods for selectively targeting cancer stem cells
03/13/2014WO2014036623A1 N‑substituted chiral aromatic oxazolidines, synthesis process, pharmaceutical composition and use
03/13/2014WO2014036620A1 Process for manufacturing a product for treating psoriasis and product for treating psoriasis
03/13/2014WO2014036608A1 Methods and products for preventing and/or treating metastatic cancer
03/13/2014WO2014036603A1 Uses of (-)-perhexiline
03/13/2014WO2014036595A1 Compounds and methods for treating diseases or conditions associated with the central nervous system and/or neurite outgrowth
03/13/2014WO2014016849A9 Novel triazine compounds
03/13/2014WO2014016660A3 Process for preparation of darunavir
03/13/2014WO2014015167A3 5,5-heteroaromatic anti-infective compounds
03/13/2014WO2014015137A3 Compositions and methods for treating dysproliferative diseases
03/13/2014WO2014015136A3 Methods for inhibition of bnip3 and prevention and treatment of ischemia reperfusion injury by tetra-o-methyl nordihydroguaiaretic acid
03/13/2014WO2014015024A3 Inhibitors of alpha-crystallin aggregation for the treatment for cataract
03/13/2014WO2014012902A3 Melanosome transport inhibition for the treatment of melanoma
03/13/2014WO2014011895A3 High solubility acid salts, intravenous dosage forms, nutrition supplementation and methods of use thereof
03/13/2014WO2014007781A3 Inhalation compositions
03/13/2014WO2014007771A3 Inhalation compositions comprising muscarinic receptor antagonist
03/13/2014WO2013190509A3 Preparation of intermediates of boceprevir
03/13/2014WO2013190508A3 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
03/13/2014WO2013190497A3 Compositions and methods for treatment of inflammatory diseases of the lung
03/13/2014WO2013188813A3 Novel therapeutics for brain cancer
03/13/2014WO2013184876A8 Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
03/13/2014WO2013182946A3 Vilazodone hydrobromide, process for its preparation and vilazodone polymorphs
03/13/2014WO2013181251A9 Crizotinib hydrochloride salt in crystalline
03/13/2014WO2013179144A3 Chemical suppressors of neurotoxicity in synucleinopathic diseases
03/13/2014WO2013177536A3 Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
03/13/2014WO2013175474A9 Selective inhibitors of undifferentiated cells
03/13/2014WO2013175316A3 Dopaminergic modulators for the treatment of huntington's disease
03/13/2014WO2013151672A3 Modified polynucleotides for the production of oncology-related proteins and peptides
03/13/2014WO2013030702A8 Anthelmintic formulations and treatments
03/13/2014WO2012122011A3 Amino-quinolines as kinase inhibitors
03/13/2014WO2012118563A3 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
03/13/2014WO2012096928A3 Pyrimidinone derivatives as fatty acid synthase inhibitors
03/13/2014WO2012088033A3 Novel pharmaceutical composition
03/13/2014WO2011031304A3 Compositions and methods for enhancing cognitive and related functions in animals
03/13/2014WO2010102267A3 Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
03/13/2014US20140073703 Phytol as a cholesterol lowering agent
03/13/2014US20140073702 Lupeol anti-tumor agent and uses thereof
03/13/2014US20140073701 Methods of preventing, treating and diagnosing disorders of protein aggregation
03/13/2014US20140073699 Combination Therapies for the Treatment of Obesity
03/13/2014US20140073698 Pharmaceutical composition comprising ketoprofen
03/13/2014US20140073697 Delivery of ibuprofen and other compounds
03/13/2014US20140073696 Combination composition
03/13/2014US20140073695 Method for the preparation of a levothyroxine solution
03/13/2014US20140073694 Cystamine analogues for the treatment of parkinson's disease
03/13/2014US20140073693 Use of ketone esters for prevention of cns oxygen toxicity
03/13/2014US20140073692 Highly purified ethyl epa and other epa derivatives
1 ... 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 ... 7860